Mediar Therapeutics

mediartx.com

mediartx.com • Series B 2026 • 51-200 employees • Startup • New

Series B 2026 • 51-200 employees • Startup • New

Actively hiring

Biotechnology

Health Care

As featured in

Wspa

Fox4Kc

Nature

Overview

News

Salaries

Products

People

Growth

Offices

Financials

Funding and backers

Total raised

$76M

1 round on record

Latest round

$76M

Series B · Jan 2026 · 8 mo ago

Team

51-200

employees, estimated range

Backers

Novartis Venture Fund, Sofinnova Partners

The money's age

Fresh money

8 months since the last round · not hiring

Momentum

20/100

fresh money

Last sign of life

this month

a posting or a news item

The story so fareach stage dated by its source: the company's releases, the press, registers, filings

Jan 7 Raised a round Series B $76M · led by Amplitude Ventures · YahooFinance

Funding rounds

Round	Date	Amount	Investors	Source
Series B	Jan 2026	$76M	Amplitude Ventures lead, ICG lead	YahooFinance

Backed byfrom the funds' portfolios and accelerator catalogs

Novartis Venture Fund fund

Sofinnova Partners fund

Similar startupsby what they do, their industry and backers

Granite Bio AG4 roles

Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis. Granite Bio develops first-in-class therapeutic antibodies depleting…

Elevara Medicines

Elevara Medicines is a clinical-stage biotech. ELV001 targets fibroblast-like synoviocytes and synergizes with DMARDs to achieve clinical…

HumanityVenture round $9M · 4 yr ago • Founded 2020 • 11-50 employees

Help all of humanity to slow down, or even reverse aging and maximise healthspan. Be a part of it.

Harbor11-50 employees

Harbor is clinical trial software built for compliance and designed for humans. Get better data, quicker answers, and faster submissions.

Alentis TherapeuticsSeries D $181.4M · 22 mo ago • Founded 2019 • 51-200 employees

THE CLAUDIN-1 COMPANY Treat cancer and reverse fibrosis We are a clinical-stage biotech company with a mission to treat cancer and reverse…

Overview

New perspective. Novel targets. Clinical trials. The myofibroblast is responsible for depositing collagen, extracellular matrix, and maintaining the pro-fibrotic micro-environment in organ systems. By deactivating the myofibroblast, we hope to slow fibrosis and possibly reverse it.

News

News NewsMedical 5 months ago

Qureight to support Mediar Therapeutics' Phase 2 trial of MTX-474 in diffuse cutaneous Systemic Sclerosis

Qureight, an end-to-end imaging CRO that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease, and Mediar Therapeutics (Mediar), a clinical-stage biotechnology company advancing first-in-clas

Report

News bioworld.com 9 months ago

Series B financing at Mediar Therapeutics

Mediar Therapeutics Inc. has announced an oversubscribed $76 million series B financing to support its novel anti-fibrotics through clinical studies. The funding will also be used to advance MTX-439 into phase I for the treatment of chronic kidney disease

Report

News Pulse 2.0 9 months ago

Mediar Therapeutics: $76 Million Series B Raised As Fibrosis Programs Advance

Mediar Therapeutics, a clinical-stage biotech developing first-in-class therapies designed to halt fibrosis, said it closed an oversubscribed $76 million Series B financing co-led by Amplitude Ventures and ICG as it advances a portfolio of antibody progra

Report

News YahooFinance 9 months ago

Mediar Therapeutics Announces Oversubscribed $76 Million Series B Financing and Clinical Advancement of First-in-Class Fibrosis Portfolio

Mediar Therapeutics, Inc., a clinical-stage biotechnology company advancing first-in-class therapies designed to halt fibrosis, today announced an oversubscribed $76 million Series B financing co-led by Amplitude Ventures and ICG, with participation from

Report

Press release kxan.com 1 year ago

Mediar Therapeutics Doses First Patient in Phase 2 WISPer Trial of MTX-463 for Idiopathic Pulmonary Fibrosis Read more

Report

Blog 1 year ago

Eli Lilly pushes into pulmonary fibrosis with $99M deal for Mediar's midphase prospect

Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in upfront and near-term payments for global rights to an asset that is entering phase 2. The deal, which includes up to $687 million i

Report

Blog 1 year ago

Lilly ventures into pulmonary fibrosis with startup Mediar

Eli Lilly entered into a global licensing deal with Mediar Therapeutics, aiming to develop a first-in-class therapy for idiopathic pulmonary fibrosis. The back-heavy deal will see Lilly hand over $99 million in upfront payment and near-term milestones, ac

Report

Press release wspa.com 1 year ago

Mediar Therapeutics Enters into Global Licensing Agreement with Lilly to Advance First-in-Class WISP1 Antibody for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) Read more

Report

Press release fox4kc.com 2 years ago

Mediar Therapeutics Initiates Second Clinical Program in Portfolio of Novel First-In-Class Antibodies Designed to Halt Fibrosis Read more

Report

News Nature Index 2 years ago

Mediar Therapeutics, Inc.

Research outputs, collaborations and relationships for Mediar Therapeutics, Inc.

Report

Show more news

Financials

Total raised

$76M

Latest round

Series B

Funding rounds

Round	Announced	Amount
Series B	2026	$76M	Details